List of Tables
Summary Table: Global Market for Women’s Health Therapeutics, by Condition/Disorder/Disease, Through 2025
Table 1: Life Expectancy at Birth, by Region
Table 2: Pipeline Compounds for Endometriosis
Table 3: Pipeline Compounds for Uterine Fibroids
Table 4: Pipeline Compounds for All Other Indications
Table 5: Pipeline Compounds for Osteoporosis
Table 6: Description of Relugolix
Table 7: Description of Proellex
Table 8: Global Market for Women’s Health Therapeutics, by Condition/Disorder/Disease, Through 2025
Table 9: FDA Approved Estrogen-only Medicines
Table 10: FDA-Approved Progestin-Only Medicines
Table 11: FDA Approved Combination Estrogen and Progestin Medicines
Table 12: FDA Approved Combination Estrogen and Hormone Medicines
Table 13: Vagifem (10 mcg), Patent Expiration
Table 14: Global Market for Therapeutics for Menopause, by Region, Through 2025
Table 15: Prolia/XGEVA (Denosumab) Patent Expiration
Table 16: Global Market for Therapeutics for Postmenopausal Osteoporosis, by Region, Through 2025
Table 17: Global Market for Therapeutics for Endometriosis, by Region, Through 2025
Table 18: Global Market for Therapeutics for Polycystic Ovary Syndrome, by Region, Through 2025
Table 19: Global Market for Therapeutics for Pregnancy Disorders and Management, by Region, Through 2025
Table 20: Global Market for Therapeutics for Other Types of Women’s Health Conditions, Disorders and Diseases, by Region, Through 2025
Table 21: Global Market for Therapeutics for Women’s Health Conditions, Disorders and Diseases, by Region, Through 2025
Table 22: North American Market for Women’s Health Therapeutics, by Condition/Disorder/Disease, Through 2025
Table 23: European Market for Therapeutics for Women’s Health, by Condition/Disorder/Disease, Through 2025
Table 24: Asia-Pacific Market for Women’s Health Therapeutics, by Condition/Disorder/Disease, Through 2025
Table 25: South American Market for Therapeutics for Women’s Health, by Condition/Disorder/Disease, Through 2025
Table 26: Middle East and African Market for Women’s Health Therapeutics, by Condition/Disorder/Disease, Through 2025
Table 27: Company Market Share Analysis, by Indication, 2017
Table 28: Tier III Companies
Table 29: Patent Review
Table 30: Marketed Products for Postmenopausal Osteoporosis
Table 31: AbbVie Inc.: Marketed Products
Table 32: AbbVie Inc.: Net Revenue, 2017-2019
Table 33: Allergan Plc: Marketed Products
Table 34: Allergan Plc: Net Revenue, 2017-2019
Table 35: Amgen Inc.: Marketed Products, 2016
Table 36: Amgen Inc.: Net Revenue, 2017-2019
Table 37: Bayer AG: Marketed Products
Table 38: Bayer AG: Net Revenue, 2018 and 2019
Table 39: Daiichi Sankyo Co. Ltd.: Marketed Products
Table 40: Daiichi Sankyo Co. Ltd.: Net Revenue, 2017 and 2018
Table 41: Eli Lilly and Co.: Marketed Products
Table 42: Eli Lilly and Co.: Net Revenue, 2018 and 2019
Table 43: Johnson & Johnson Inc.: Marketed Products, 2020
Table 44: Johnson & Johnson Inc.: Net Revenue, 2017-2019
Table 45: Merck & Co. Inc.: Marketed Products
Table 46: Merck & Co. Inc.: Net Revenue, 2017-2019
Table 47: Merck KGaA: Marketed Products
Table 48: Novo Nordisk: Marketed Products
Table 49: Novo Nordisk: Net Revenue, 2017-2019
Table 50: Pfizer Inc.: Marketed Products by Indication, 2020
Table 51: Pfizer Inc.: Net Revenue, 2017-2019
Table 52: Glossary of Terms Used in Women’s Health Therapeutics
Table 53: Abbreviations Used in Women’s Health Therapeutics
List of Figures
Summary Figure: Global Market for Women’s Health Therapeutics, by Condition/Disorder/Disease 2019-2025
Figure 1: Distribution of Older Population, by Age Group and Sex, 2017
Figure 2: Distribution of Older Population, by Age Group and Sex, 2050
Figure 3: Funding for Research, by Disease, 2014-2016
Figure 4: Funding for Research on Women’s Health, 2014-2016
Figure 5: Insurance Coverage in The U.S., by Type of Healthcare Provider, 2014
Figure 6: Global Market for Women's Health Therapeutics, 2019-2025
Figure 7: Global Market Shares of Women’s Health Therapeutics, by Condition/Disorder/Disease, 2019
Figure 8: Global Market Shares of Women’s Health Therapeutics, by Condition/Disorder/Disease, 2025
Figure 9: Global Market for Therapeutics for Menopause, 2019-2025
Figure 10: Global Market for Therapeutics for Menopause, by Region, 2019-2025
Figure 11: Australian Rate of Hospitalization for Osteoporosis, People Aged 50 and Over, 2015-2016
Figure 12: Global Market for Therapeutics for Postmenopausal Osteoporosis, 2019-2025
Figure 13: Global Market for Therapeutics for Postmenopausal Osteoporosis, by Region, 2019-2025
Figure 14: Global Market for Therapeutics for Endometriosis, 2019-2025
Figure 15: Global Market for Therapeutics for Endometriosis, by Region, 2019-2025
Figure 16: Global Market for Therapeutics for Polycystic Ovary Syndrome, 2019-2025
Figure 17: Global Market for Therapeutics for Polycystic Ovary Syndrome, by Region, 2019-2025
Figure 18: Global Market for Therapeutics for Pregnancy Disorders and Management, 2019-2025
Figure 19: Global Market for Therapeutics for Pregnancy Disorders and Management, by Region, 2019-2025
Figure 20: Global Market for Therapeutics for Other Types of Women’s Health Conditions, Disorders and Diseases, 2019-2025
Figure 21: Global Market for Therapeutics for Other Types of Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 22: Global Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, by Region, 2019-2025
Figure 23: North American Market for Therapeutics for Women’s Health Conditions, Disorders and Diseases, 2019-2025
Figure 24: North American Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2019
Figure 25: North American Market Shares of Therapeutics for Women’s Health, by Condition/Disorder/Disease, 2025
Figure 26: North American Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, by Country, 2019-2025
Figure 27: U.S. Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 28: Canadian Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 29: Mexican Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 30: European Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 31: European Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2019
Figure 32: European Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2025
Figure 33: European Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, by Country, 2019-2025
Figure 34: U.K. Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 35: German Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 36: French Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 37: Spanish Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 38: Italian Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 39: Rest of European Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 40: Asia-Pacific Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 41: Asia-Pacific Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2019
Figure 42: Asia-Pacific Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2025
Figure 43: Asia-Pacific Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, by Country, 2019-2025
Figure 44: Chinese Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 45: Japanese Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 46: Indian Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 47: South Korean Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 48: Rest of Asia Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 49: South American Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 50: South American Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2019
Figure 51: South American Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2025
Figure 52: Middle East and African Market for Therapeutics for Women's Health Conditions, Disorders and Diseases, 2019-2025
Figure 53: Middle East and African Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2019
Figure 54: Middle East and African Market Shares of Therapeutics for Women's Health, by Condition/Disorder/Disease, 2025
Figure 55: Global Women's Health Therapeutics Market Share Analysis, 2019
Figure 56: AbbVie Inc.: Revenue Share, by Region, 2018
Figure 57: Allergan Plc: Revenue Share, by Business Segment, 2017
Figure 58: Amgen Inc: R&D Expenditures, 2014-2016
Figure 59: Amgen Inc.: Revenue Share, by Region, 2018
Figure 60: Bayer AG: Revenue Share, by Region, 2018
Figure 61: Bayer AG: Revenue Share, by Business Segment, 2018
Figure 62: Daiichi Sankyo Co. Ltd.: R&D Expenditures, 2014-2016
Figure 63: Daiichi Sankyo Co. Ltd.: Revenue Share, by Business Segment, 2018
Figure 64: Eli Lilly and Co.: Revenue Share, by Business Segment, 2018
Figure 65: Eli Lilly and Co.: Revenue Share, by Region, 2018
Figure 66: Johnson & Johnson Inc.: Revenue Share, by Business Segment, 2018
Figure 67: Johnson and Johnson Inc.: Revenue Share, by Region, 2018
Figure 68: Merck & Co. Inc.: Revenue Share, by Business Segment, 2018
Figure 69: Merck & Co. Inc.: Revenue Share, by Region, 2018
Figure 70: Novo Nordisk: Revenue Share, by Region, 2018
Figure 71: Novo Nordisk: Revenue Share, by Business Segment, 2018
Figure 72: Pfizer Inc.: Revenue Share, by Region, 2018
Figure 73: Pfizer Inc.: Revenue Share, by Business Segment, 2018
